Affymax Inc AFFY:Over The Counter Market

Last Price$0.0072Over The Counter Market Previous Close - Last Trade as of 1:37PM ET 8/12/22
Over The Counter Market 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$0.0201 (10,000)
Ask (Size)$0.0439 (10,000)
Day Low / HighN/A - N/A
Volume2.5 K
 

View Biotechnology IndustryPeer Comparison as of 08/12/2022

 

Affymax Inc ( OTC )

Price: $0.0072
Change: 0.00 (0.00%)
Volume: 2.5 K
1:37PM ET 8/12/2022
 
 

Pathfinder Cell Therapy Inc ( OTC )

Price: $0.00
Change: 0.00 (0.00%)
Volume: 700.00
1:09PM ET 11/10/2021
 
 

Predictive Technology Group Inc ( OTC )

Price: $0.0007
Change: 0.00 (0.00%)
Volume: 600.00
1:10PM ET 8/12/2022
 
 

DNAPrint Genomics Inc ( OTC )

Price: $0.00
Change: 0.00 (0.00%)
Volume: 2.3 K
2:55PM ET 8/02/2022
 
 

Optigenex Inc ( OTC )

Price: $1.00
Change: 0.00 (0.00%)
Volume: 4.00
12:28PM ET 1/19/2022
 

Read more news Recent News

No news stories available at this time.

View all Commentary and Analysis

No news stories available at this time.

Company Profile

Business DescriptionAffymax, Inc. is a biopharmaceutical company. It is engaged in the developing of nephrology and specialty care space by delivering innovative therapeutical offerings to patients and healthcare providers. The company was founded on July 20, 2001 and is headquartered in New York, NY. View company web site for more details
Address600 Fifth Avenue
New York, New York 10020
Phone+1.650.812.8700
Number of Employees4

Company Highlights

Price Open$0.0072
Previous Close$0.0072
52 Week Range$0.0002 - 0.05
Market Capitalization$536.3 K
Shares Outstanding74.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings AnnouncementN/A

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings0.09
Earnings per Share$0.08
Beta vs. S&P 500N/A
Revenue$1.4 M
Net Profit Margin6,414.29%
Return on Equity2,006.70%

Analyst Ratings as of 07/24/2013

Buy
0
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset